RECRUITING

Biomarkers of Exposure and Effect in Standardized Research E-cigarette (SREC) Users

Talk to us

Conditions

Smoking, Cigarette

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This study is focused on characterizing the toxic and carcinogenic potential of the Standardized Research E-cigarette (SREC) developed by the National Institute on Drug Abuse. In the environment of continuously changing e-cigarette market, SREC was developed as a model e-cigarette that will remain available for an extended period of time and can be used as a bridging element in various studies aimed at evaluating the value and limitations of e-cigarettes as tobacco risk reduction tools. Our overall goal is to generate initial reference data on chemical exposures and associated effects in smokers switching to SREC.

Official Title

Biomarkers of Exposure and Effect in Standardized Research E-cigarette (SREC) Users

Quick Facts

Study Start:2022-05-11
Study Completion:2026-01-20
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT04003805

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 65 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Male or female smokers who are 18-65 years of age and are willing to stop smoking and completely switch to e-cigarettes or medicinal nicotine;
  2. * Report smoking ≥ 5 cigarettes daily and not using any other nicotine or tobacco product;
  3. * Biochemically confirmed regular smoking status by a NicAlert test level of 6;
  4. * Smoking daily for at least 1 year and no serious quit attempts (e.g., quit for 24 hours or longer) in the last 3 months (to ensure stability of daily smoking, particularly for those randomized to the continued smoking group);
  5. * No unstable and significant medical or psychiatric conditions as determined by medical history and Prime-MD (to ensure safety of the subject, to minimize the effects of poor health on biomarker measures and to maximize compliance to study procedures);
  6. * Subjects are in good physical health (no unstable medical condition);
  7. * Subjects are in stable, good mental health (e.g. not currently, within the past 6 months, experiencing unstable or untreated psychiatric diagnosis, including substance abuse);
  8. * Subjects who are not taking anti-inflammatory medications or any medications that affect relevant metabolic enzymes;
  9. * Women who are not pregnant or nursing or planning to become pregnant;
  10. * Subject has provided written informed consent to participate in the study (adolescents under the age of 18 will be excluded because this project involves continued use of tobacco products and new tobacco products).
  1. * Regular tobacco or nicotine product use (e.g., 9 days in last 30 days) other than cigarettes;
  2. * Currently using nicotine replacement or other tobacco cessation products;
  3. * Significant immune system disorders, respiratory diseases, kidney or liver diseases or any other medical disorders that may affect biomarker data;
  4. * Unstable health conditions (any significant serious, unstable medical condition including, but not limited to, cardiovascular disease, unstable COPD, seizure disorder and cancer, as determined by the licensed medical professional);
  5. * Unstable mental health (to be determined by medical history, CESD, Prime-MD after review by the licensed medical professional);
  6. * Excessive drinking (e.g., 5 or more drinks daily) or problems with drinking or drugs (e.g., self-report of binge drinking alcohol or treatment for drug or alcohol abuse within last 3 months); to be assessed by PI or licensed medical professional;
  7. * Blood alcohol test \> 0.01 (g/dL) as measured by a breath sample at screening (participants failing the breath alcohol screen will be allowed to re-screen once;
  8. * Positive toxicology screen for any of the following drugs: cocaine, opiates, methadone, benzodiazepines, barbiturates, amphetamines, methamphetamines, and PCP. Failing temperature strip for the sample. Marijuana will be tested for, but will not be an exclusionary criterion. Participants with valid prescriptions for opiates, benzodiazepines, barbiturates, amphetamines or methadone will not be excluded. Participants failing the toxicology screen will be allowed to re-screen once;
  9. * Pregnant or breastfeeding;
  10. * Failure to agree to take adequate protection to avoid becoming pregnant during the study;
  11. * Vital signs outside of the following range (participants failing for vital signs will be allowed to re-screen once):
  12. * Systolic BP greater than or equal to 160 mm/hg
  13. * Diastolic BP greater than or equal to 100 mm/hg
  14. * Systolic BP below 90 mm/hg and symptomatic (dizziness, extreme fatigue, difficulty thinking, inability to stand or walk, feeling faint)
  15. * Diastolic BP below 50 mm/hg and symptomatic (dizziness, extreme fatigue, difficulty thinking, inability to stand or walk, feeling faint)
  16. * Heart rate greater than or equal to 105 bpm
  17. * Heart rate lower than 45 bpm and symptomatic (dizziness, extreme fatigue, difficulty thinking, inability to stand or walk, feeling faint)
  18. * Expired air carbon monoxide (CO) level greater than 80 ppm;
  19. * Self-reported allergies to propylene glycol or vegetable glycerin;
  20. * Adverse reactions when previously using electronic cigarettes;
  21. * Household member enrolled in the study concurrently;
  22. * Unable to read for comprehension or completion of study documents;
  23. * Unstable living environment that would compromise the ability to attend visits, sequester study products or complete study procedures outside of visits.

Contacts and Locations

Study Contact

Hanna Vanderloo, RN, MSN
CONTACT
612.624.4983
hannav@umn.edu

Principal Investigator

Irina Stepanov, PhD
PRINCIPAL_INVESTIGATOR
University of Minnesota, Division of Environmental Health Sciences

Study Locations (Sites)

University of Minnesota, Masonic Cancer Center
Minneapolis, Minnesota, 55455
United States

Collaborators and Investigators

Sponsor: Masonic Cancer Center, University of Minnesota

  • Irina Stepanov, PhD, PRINCIPAL_INVESTIGATOR, University of Minnesota, Division of Environmental Health Sciences

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2022-05-11
Study Completion Date2026-01-20

Study Record Updates

Study Start Date2022-05-11
Study Completion Date2026-01-20

Terms related to this study

Additional Relevant MeSH Terms

  • Smoking, Cigarette